Treatment of Experimental Group B Streptococcal Infection with Hybridoma Antibody

Functional Activity of Class-Specific Antibodies to Type III, Group B Streptococcus

“…Recently, immunospecific murine monoclonal IgM antibodies have been viewed with interest as potential immunotherapeutic agents for infants born too prematurely to receive IgG in a theoretically "protective" level (16). The efficacy of murine monoclonal class-specific antibodies for protection in invasive 111-GBS experimental infection is well documented (2,(17)(18). Lack of availability of a suitable source of IgM has previously prevented a functional comparison of naturally acquired class-specific antibodies to type 111-GBS.…”

The Effect of Administration of Immunoglobulin to Newborn Rats with Escherichia coli Sepsis and Meningitis

“…In clinical studies of neonatal GBS disease, a lack of opsonic antibody toward GBS correlates with a poor outcome (25). Furthermore, in experimental models of neonatal GBS sepsis, infected animals treated with anti-GBS antibody exhibit markedly improved survival (26)(27)(28). Preparations of MISG have been successfully used as a source of anti-GBS antibody, improving the outcome of infected neonatal rats (1 3, 15, 16).…”

Group B Streptococcal Infections

“…In experimental infection with type III GBS, monoclonal IgM antibody to type III polysaccharide stimulated the release of neutrophils from storage pools into the bloodstream and improved neutrophil migration to the site of infection [387]. This facilitation of neutrophil function by type III-specific antibody improved survival in animals only if the antibody was administered when neutrophil reserves were intact (very early in infection) [388]. Antibody recipients did not become neutropenic and did not experience depletion of their neutrophil reserves.…”